Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

Related Articles by Review for PubMed (Select 10922406)

1.

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

Marks PA, Richon VM, Rifkind RA.

J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6. Review.

2.

Histone deacetylase inhibitors as new cancer drugs.

Marks PA, Richon VM, Breslow R, Rifkind RA.

Curr Opin Oncol. 2001 Nov;13(6):477-83. Review.

PMID:
11673688
3.

Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.

Kim DH, Kim M, Kwon HJ.

J Biochem Mol Biol. 2003 Jan 31;36(1):110-9. Review.

4.

Histone deacetylase inhibitors in cancer treatment.

Vigushin DM, Coombes RC.

Anticancer Drugs. 2002 Jan;13(1):1-13. Review.

PMID:
11914636
5.

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

PMID:
17504226
6.

Histone deacetylase inhibitors in programmed cell death and cancer therapy.

Marks PA, Jiang X.

Cell Cycle. 2005 Apr;4(4):549-51. Epub 2005 Apr 28. Review.

7.

Development of histone deacetylase inhibitors for cancer treatment.

Marchion D, Münster P.

Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. Review.

PMID:
17428177
8.

Role of histone deacetylase inhibitors in the treatment of cancer (Review).

Mei S, Ho AD, Mahlknecht U.

Int J Oncol. 2004 Dec;25(6):1509-19. Review.

PMID:
15547685
9.
10.

Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view.

Vanhaecke T, Papeleu P, Elaut G, Rogiers V.

Curr Med Chem. 2004 Jun;11(12):1629-43. Review.

PMID:
15180568
11.

Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.

Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A.

Curr Pharm Biotechnol. 2007 Dec;8(6):388-400. Review.

PMID:
18289048
12.

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

Zhu WG, Otterson GA.

Curr Med Chem Anticancer Agents. 2003 May;3(3):187-99. Review.

PMID:
12769777
13.

Histone deacetylases and cancer: causes and therapies.

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK.

Nat Rev Cancer. 2001 Dec;1(3):194-202. Review.

PMID:
11902574
14.

Histone deacetylase as a new target for cancer chemotherapy.

Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6. Review.

PMID:
11587361
15.

Targeted histone deacetylase inhibition for cancer therapy.

Vigushin DM, Coombes RC.

Curr Cancer Drug Targets. 2004 Mar;4(2):205-18. Review.

PMID:
15032670
16.

Histone deacetylase inhibitors: from target to clinical trials.

Kelly WK, O'Connor OA, Marks PA.

Expert Opin Investig Drugs. 2002 Dec;11(12):1695-713. Review.

PMID:
12457432
17.

HDAC inhibitors for the treatment of cancer.

Secrist JP, Zhou X, Richon VM.

Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Review.

PMID:
14763127
18.

Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?

Papeleu P, Vanhaecke T, Elaut G, Vinken M, Henkens T, Snykers S, Rogiers V.

Crit Rev Toxicol. 2005 Apr-May;35(4):363-78. Review.

PMID:
15989141
19.

Histone acetylation and the cell-cycle in cancer.

Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG.

Front Biosci. 2001 Apr 1;6:D610-29. Review.

PMID:
11282573
20.

Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.

Balakin KV, Ivanenkov YA, Kiselyov AS, Tkachenko SE.

Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. Review.

PMID:
17896917
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk